zurich jul 2015
DESCRIPTION
http://www.cddep.org/sites/default/files/zurich.jul_.2015.pdfTRANSCRIPT
![Page 1: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/1.jpg)
Economics of Antibiotic Resistance
Ramanan Laxminarayan
Latsis Symposium, 2015
![Page 2: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/2.jpg)
I. Increasing incomes and access to antibiotics are saving lives but are not a good substitute for public health
![Page 3: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/3.jpg)
Bacterial diseases are still major killers in developing countries because of lack
of access to antibiotics
O’Brien et al, Lancet 2009
![Page 4: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/4.jpg)
What are we asking of antibiotics?
![Page 5: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/5.jpg)
Substitute for immunization, infection control and water/
sanitation
South Asia
![Page 6: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/6.jpg)
Substitute for immunization, infection control and water/
sanitation
Sub-Saharan Africa
![Page 7: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/7.jpg)
Kyaw MH et al. N Engl J Med 2006;354:1455-1463.
Vaccines can be effective Invasive disease caused by Pneumococci in children under
two declined in the US post pneumo vaccination
![Page 8: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/8.jpg)
Effect of PCV7 introduction on antibiotic prescriptions and ambulatory care visits
Zhou et al, Pediatrics 2008
![Page 9: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/9.jpg)
Effect of PCV7 introduction on antibiotic prescriptions and ambulatory care visits
Zhou et al, Pediatrics 2008
Antibiotic prescriptions attributable to acute otitis media decreased from 1244 to 722 prescriptions per 1000 person-years – a 41.9% reduction.
![Page 10: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/10.jpg)
Antibiotic consumption is increasing in
developing countries...
Source: Based on data obtained under license from IMS Health MIDAS ™ (January 2005-December 2010); IMS Health Incorporated. All Rights Reserved.
0
5000
10000
15000
20000
25000
BRAZIL, RETAIL INDIA, RETAIL VIETNAM, RETAIL NORWAY, RETAIL USA, RETAIL
Sta
nd
ard
Un
its p
er
1000
po
pu
latio
n
Per capita total antibiotic use, retail sector, 2005-2010
2005
2006
2007
2008
2009
2010
![Page 11: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/11.jpg)
![Page 12: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/12.jpg)
Last-resort drugs are widely sold on the
retail market..
0
0.5
1
1.5
2
2.5
3
3.5
4
BRAZIL, RETAIL VIETNAM, RETAIL INDIA, RETAIL USA, RETAIL NORWAY, RETAIL
Sta
nd
ard
Un
its p
er
1000
po
pu
latio
n
Per capita total carbapenem use, retail sector, 2005-2010
2005
2006
2007
2008
2009
2010
Source: Based on data obtained under license from IMS Health MIDAS ™ (January 2005-December 2010); IMS Health Incorporated. All Rights Reserved.
![Page 13: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/13.jpg)
Hospital use of carbapenems is rapidly growing
0
10
20
30
40
50
60
70
VIETNAM, HOSPITAL CHINA, HOSPITAL NORWAY, HOSPITAL USA, HOSPITAL
Sta
nda
rd U
nits
pe
r 100
0 p
op
ula
tion
Per capita total carbapenem use, hospital sector, 2005-2010
2005
2006
2007
2008
2009
2010
Source: Based on data obtained under license from IMS Health MIDAS ™ (January 1999-December 2010); IMS Health Incorporated. All Rights Reserved.
![Page 14: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/14.jpg)
![Page 15: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/15.jpg)
Van Boeckel et al, Lancet Inf. Dis., 2014
![Page 16: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/16.jpg)
Van Boeckel et al, Lancet Inf. Dis., 2014
![Page 17: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/17.jpg)
![Page 18: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/18.jpg)
Van Boeckel et al, Lancet Inf Dis, 2014
![Page 19: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/19.jpg)
Antibiotic sales data can predict influenza in the United States
Polgreen, Laxminarayan et al. ICHE, 2010
![Page 20: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/20.jpg)
![Page 21: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/21.jpg)
Mortality outcomes are worse in neonates with resistant infections
Kayange M, Kamugisha E, Mwizamholya DL, Jeremiah S, Mshana SE. 2010. Predictors of posiCve blood culture and deaths among neonates with suspected neonatal sepsis in a terCary hospital, Mwanza-‐ Tanzania. BMC Pediatrics 10: 39.
149
58
36 9
151
91
55
23
0
10
20
30
40
50
60
Culture Gram Reaction ESBL MRSA
Dea
th (%
)
Parameter
Positive
Negative
![Page 22: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/22.jpg)
![Page 23: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/23.jpg)
II. Drivers of antibiotic use relate to incentives and behavior of patients, physicians, pharma, payers and healthcare institutions.
![Page 24: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/24.jpg)
Incentives for Physicians
• Satisfying patient expectations
![Page 25: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/25.jpg)
Dosh, J Fam Pr 1999
![Page 26: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/26.jpg)
Health insurance increases prescribing
Foxman et, RAND Corporation,1987
![Page 27: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/27.jpg)
Health insurance increases prescribing
Foxman et, RAND Corporation,1987
![Page 28: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/28.jpg)
What happens when antibiotics are provided free?
Overall increase in antibiotic prescriptions as well as substitutions to covered antibiotics from not-covered antibiotics.
Li and Laxminarayan, Health Economics, 2013
![Page 29: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/29.jpg)
What happens when antibiotics are provided free?
Overall increase in antibiotic prescriptions as well as substitutions to covered antibiotics from not-covered antibiotics.
Li and Laxminarayan, Health Economics, 2013
![Page 30: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/30.jpg)
Hospital Incentives
• Antibiotics may be a substitute for infection control
• Infection control is often not compensated but longer hospital stays are beneficial to the hospital
![Page 31: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/31.jpg)
III. In the livestock sector, the tremendous increase in demand for animal protein will drive continued use of antibiotics in sub-therapeutic concentrations without changes in regulatory policy
![Page 32: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/32.jpg)
Increase in demand for poultry in India and China between 2000 and 2030
FAO, 2011
![Page 33: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/33.jpg)
Amounts, in mg, of veterinary antibacterial agents sold in 2007 per kg biomass of pig meat, poultry meat and cattle meat produced plus estimated live weight of dairy cattle. *2005 data.
**The substances included vary from country to country.
Grave K et al. J. Antimicrob. Chemother. 2010;65:2037-2040
![Page 34: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/34.jpg)
![Page 35: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/35.jpg)
Global antimicrobial consumption in livestock (top) and average standard deviation of estimates
(bottom)
van Boeckel et al, PNAS, 2015
![Page 36: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/36.jpg)
Largest consumers of antimicrobials in livestock in 2010 and 2030
A) Largest five consumers of antimicrobials in livestock in 2010 B) Largest five consumers of antimicrobials in livestock in 2030 (projected). C) Largest Increase in antimicrobial consumption between 2010 and 2030, D) Largest relative increase in Antimicrobial consumption between 2010 and 2030.
van Boeckel et al, PNAS, 2015
![Page 37: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/37.jpg)
• Global average annual consumption of antimicrobials per kilogram of animal produced was 172 mgs per kg for cattle, chicken and pigs
• Global consumption of antimicrobials in food animal production was estimated at 63,151 (±1,560) tonnes in 2010 and is projected to rise by 67%, to 105,596 (±3,605) tonnes by 2030, § In hotspots like India where areas of high consumption (30
kg per km2) for industrial poultry production are expected to grow 312% by 2030
(van Boeckel et al, PNAS, 2015).
van Boeckel et al, PNAS, 2015
![Page 38: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/38.jpg)
Laxminarayan et al OECD Report, 2014
![Page 39: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/39.jpg)
Difference in average daily growth between animals raised with and without AGPs
Laxminarayan et al OECD Report, 2014
![Page 40: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/40.jpg)
Response by livestock to supplementation with growth promoters
Barug et al., 2006
![Page 41: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/41.jpg)
Productivity reductions and costs per produced pig incurred by removing AGPs
Laxminarayan et al OECD Report, 2014
![Page 42: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/42.jpg)
Effect of Danish ban on AGPs
DANMAP 97 (1998) DANMAP 2012 (2013); DANMAP 2004 (2005)
![Page 43: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/43.jpg)
Categories of regulatory framework for the use of antimicrobial for growth promotion
![Page 44: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/44.jpg)
Potential loss in annual meat production following AGP withdrawal (in %)
Laxminarayan et al OECD Report, 2014
![Page 45: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/45.jpg)
Potential loss in the value of annual meat production following AGP withdrawal
Laxminarayan et al OECD Report, 2014
![Page 46: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/46.jpg)
IV. Who will pay the price of rising resistance – implications of AMR.
![Page 47: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/47.jpg)
Loss of first line drugs increases drug costs
Source: WHO Policy Perspective 2005, adapted from WHO Model Formulary, WHO Clinical Guidelines and Management Sciences for Health’s 2004 International Drug Price Indicator Guide (slide courtesy: David Heymann)
![Page 48: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/48.jpg)
Annual health gain (QALYs) in the US from procedures requiring
antibiotic prophylaxis
![Page 49: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/49.jpg)
V. Solving the problem – what can economics bring to the table?
![Page 50: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/50.jpg)
The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.
Make better use of existing antibiotics
Image Courtesy of Shutterstock
![Page 51: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/51.jpg)
Find new antibiotics
Image Courtesy of Shutterstock
![Page 52: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/52.jpg)
Is the rate of new drug development declining?
![Page 53: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/53.jpg)
Trends in development of new antibiotics
![Page 54: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/54.jpg)
Laxminarayan, Science, 2014
![Page 55: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/55.jpg)
Consider this
• Of the 61 new antibiotics approved between 1980 and 2009, 26 (43%) were withdrawn either because of toxicity or lack of market, compared with a 13% withdrawal rate for other therapeutic categories (Outterson et al 2013)
• Under the Generating Antibiotic Incentives Now (GAIN) Act in the United States new antibiotics are given 5 years of additional market exclusivity for designated Qualified Infectious Disease Products
![Page 56: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/56.jpg)
![Page 57: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/57.jpg)
![Page 58: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/58.jpg)
![Page 59: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/59.jpg)
![Page 60: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/60.jpg)
Important questions
• Do we need public subsidies for new antibiotic development or will the market respond on its own?
• What is the impact of public subsidies for new drug development on stewardship?
• How can we change the rules of the game to incentivize appropriate use of new (and existing) antibiotics?
• How do we balance access with concerns about resistance?
![Page 61: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/61.jpg)
Once an antibiotic is introduced, resistance is not far behind…
![Page 62: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/62.jpg)
What kind of innovation?
• Combination therapies that target both essential functions and resistance factors § Eg. amoxicillin-clavulanate
• Repurpose old drugs to optimize dosing levels and the duration, and route of administration § E.g.optimized dosing of colistin to reduce toxicity and
improve efficacy
• Prevent resistance by protecting non-target bacterial flora during treatments
• Point-of-care diagnostics § to identify both the cause of an infection and its sensitivity
to common antibiotics
![Page 63: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/63.jpg)
Q: What should we be willing to pay for a stewardship program that would enable a
1-year delay in the need for a $1billion investment in a new antibiotic?
A: Roughly $60 million, at a modest 6% discount rate
![Page 64: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/64.jpg)
Q: What does the US Government allocate for antimicrobial stewardship programs?
A: Zero
![Page 65: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/65.jpg)
Q: What does the Indian Government allocate for antimicrobial stewardship
programs? A: What is a stewardship program?
![Page 66: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/66.jpg)
Closing thoughts
![Page 67: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/67.jpg)
![Page 68: Zurich jul 2015](https://reader036.vdocuments.us/reader036/viewer/2022062502/579057d61a28ab900c9ee78c/html5/thumbnails/68.jpg)
www.cddep.org/garp www.extendingthecure.org
Thank you